Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 6/1/06 → 7/31/09 |
Funding
- Roche Laboratories: $18,754.00
A Randomized Study of Intermittent Capcitabine in Combination with Oxaliplatin (XELOOX Q3W) and Bevacizumab vs Intermittent Capcitabine in Combinations with Oxaliplatin (XELOX Q2W) and Bevacizumab as First-Line Treatment for Patients
- DeSimone, Philip (PI)
- Chambers, Mara (CoI)
- Kee, Bryan (CoI)